New research shows astrocytes can remove Alzheimer’s-related amyloid-beta via autophagy, offering a promising new direction ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug Administration (FDA) has approved three new drugs to treat Alzheimer’s since June 2021 ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

Swissmedic is expected to decide on the approval of the first new drug for Alzheimer’s disease in two decades. The decision ...

In a breakthrough study, researchers have imaged a network of pathways in the human brain believed to clear waste proteins ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer's disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to ...

November 13, 2017 – Gates announces he is investing $50 million in the Dementia Discovery Fund, a private-public partnership focused on Alzheimer’s research ... January 23, 2023 – Gates’ fund ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

But on that day in April 2023 ... with early Alzheimer’s symptoms. Beth Israel might offer it soon. The drug, which would be marketed as Leqembi, was considered a breakthrough on a massively ...

The United States gave the green light to lecanemab in 2023 ... down a breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due ...